SciELO - Scientific Electronic Library Online

 
vol.147 número5¿Qué representa cambiar el umbral diagnóstico de la hipertensión arterial? Guías ACC/AHA 2017 y su aplicación en PerúSinoviortesis con radioisótopos en hemofilia: Experiencia de un centro en Chile índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista médica de Chile

versão impressa ISSN 0034-9887

Resumo

KUSTIC, Domagoj et al. Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma. Rev. méd. Chile [online]. 2019, vol.147, n.5, pp.557-567. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872019000500557.

Background:

Breast cancer (BC) is the most common malignancy in women.

Aim:

To assess the impact of HER2 status on axillary lymph node (ALN) involvement in patients with invasive ductal carcinoma of no special type (IDC-NST) both at diagnosis and during the 4-year postoperative period.

Patients and Methods:

We retrospectively included 375 women with an early clinical stage of non-luminal IDC-NST who between 2007 and 2013 underwent breast surgery at a clinical hospital. They were divided into phenotype-based groups: HR+HER2-, HR+HER2+, HR-HER2+ and HR-HER2-. Only patients with sentinel lymph node (SLN) macrometastases underwent ALN dissection. If > 3 ALNs were positive, radiotherapy was delivered. All patients were treated with chemotherapy, HER2+ BC patients received trastuzumab, and hormone receptor (HR)-positive BC patients received hormonal therapy.

Results:

Larger tumor size, higher grade, HR+, HER2+ status, and lymphovascular invasion (LVI) were predictive for ALN metastases at diagnosis. The poorest overall, disease-free, and distant recurrence-free survival (OS, DFS, DRFS) were found in the HR-HER2- group, while the poorest locoregional recurrence-free survival (LRFS) was observed in HR-HER2+ and HR-HER2- groups. HER2 status was not predictor of survival.

Conclusions:

HER2+ status was predictive for ALN involvement at diagnosis but had no effect on 4-year LRFS in these patients.

Palavras-chave : Breast Neoplasms; Receptor, ErbB-2; Sentinel Lymph Node; Trastuzumab.

        · resumo em Espanhol     · texto em Inglês     · Inglês ( pdf )